LEADER 01471oam  2200385Ia 450 
001 9910697095203321
005 20230902161649.0
035   $a(CKB)5470000002383946
035   $a(OCoLC)586037897
035   $a(EXLCZ)995470000002383946
100   $a20100329d1995      ua             0
101 0 $aeng
135   $auran|||||||||
181   $ctxt$2rdacontent
182   $cc$2rdamedia
183   $acr$2rdacarrier
200 00$aGuidance for industry$b[electronic resource] $eimmediate release solid oral dosage forms : scale-up and postapproval changes, chemistry, manufacturing and controls, in vitro dissolution testing, and in vivo bioequivalence documentation
210  1$a[Rockville, Md.] :$cCenter for Drug Evaluation and Research,$d[1995]
215   $a1 electronic resource (26, 1 page)
300   $a"CMC 5"--prelim. p.
300   $a"November 1995."
320   $aIncludes bibliographical references (pages 25-26).
517   $aGuidance for industry 
606   $aSolid dosage forms$xTesting$xDocumentation$zUnited States
606   $aDrugs$xTherapeutic equivalency$xDocumentation$zUnited States
615  0$aSolid dosage forms$xTesting$xDocumentation
615  0$aDrugs$xTherapeutic equivalency$xDocumentation
712 02$aCenter for Drug Evaluation and Research (U.S.)
801  0$bGPO
801  1$bGPO
801  2$bGPO
906   $aBOOK
912   $a9910697095203321
996   $aGuidance for industry$93434577
997   $aUNINA

LEADER 01520nam  2200409Ia 450 
001 9910698831903321
005 20090526152810.0
035   $a(CKB)5470000002397549
035   $a(OCoLC)351703644
035   $a(EXLCZ)995470000002397549
100   $a20090526d2003      ua             0
101 0 $aeng
135   $auran|||||||||
181   $ctxt$2rdacontent
182   $cc$2rdamedia
183   $acr$2rdacarrier
200 00$aGuidance for industry$b[electronic resource] $erevised recommendations for donor and product management based on screening tests for syphilis
210  1$aRockville, MD :$cU.S. Dept. of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research,$d[2003]
215   $ai, 10 pages $cdigital, PDF file
300   $aTitle from PDF title page (viewed on May 26, 2009).
300   $a"Draft guidance".
300   $a"June 2003".
320   $aIncludes bibliographical references (page 8).
517   $aGuidance for industry 
606   $aBlood donors$xGovernment policy$zUnited States
606   $aBlood products$zUnited States$xEvaluation
606   $aSyphilis$zUnited States$xPrevention
615  0$aBlood donors$xGovernment policy
615  0$aBlood products$xEvaluation.
615  0$aSyphilis$xPrevention.
712 02$aCenter for Biologics Evaluation and Research (U.S.)
801  0$bGPO
801  1$bGPO
906   $aBOOK
912   $a9910698831903321
996   $aGuidance for industry$93434577
997   $aUNINA